SEC Filing Summary: PerkinElmer, Inc. (10-Q)
Business Context and Reporting Period
This is a Quarterly Report on Form 10-Q for PerkinElmer, Inc. (Note: The input metadata references "REVVITY, INC.", but the filing text explicitly identifies the registrant as PerkinElmer, Inc.). The report covers the quarterly and six-month periods ended June 27, 2004. PerkinElmer operates in three primary segments: Life and Analytical Sciences, Optoelectronics, and Fluid Sciences. During this period, the company classified its Electroformed Products and Ultraviolet Lighting businesses as discontinued operations.
Key Financial Metrics
| Metric | Three Months Ended June 27, 2004 |
Six Months Ended June 27, 2004 |
|---|---|---|
| Sales | $412.6 million | $805.2 million |
| Net Income | $20.8 million | $34.1 million |
| Diluted EPS | $0.16 | $0.26 |
| Operating Income | $39.2 million | $68.2 million |
| Cash from Operations | N/A (Quarterly) | $83.2 million |
| Cash and Equivalents | $196.7 million | $196.7 million |
| Total Debt | $489.4 million | $489.4 million |
| Gross Margin | 40.3% | 39.5% |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 10% year-over-year for both the quarter and the six-month period. This growth was driven by a 44% increase in the Fluid Sciences segment and 5-7% growth in Life and Analytical Sciences and Optoelectronics. Approximately $7.3 million (quarter) and $25.3 million (six months) of the increase was attributable to favorable foreign exchange rates.
- Profitability: Net income surged 148% for the quarter and 217% for the six-month period compared to the prior year. Operating income increased 29% (quarter) and 36% (six months).
- Margin Compression: Gross margin decreased slightly by 40 basis points to 40.3% (quarter) and 39.5% (six months), primarily due to a higher sales mix from the lower-margin Fluid Sciences segment.
- Expense Management: Selling, general, and administrative (SG&A) expenses decreased as a percentage of sales by 220 basis points (quarter) due to productivity improvements from prior restructuring. Interest expense decreased significantly due to lower outstanding borrowings and favorable interest rate swaps.
- Discontinued Operations: The company recorded a loss from discontinued operations of $0.1 million for the quarter and $0.3 million for the six months, compared to losses of $0.9 million and $2.3 million in the prior year periods.
Guidance, Outlook, and Risks
- Restructuring: The company continues to execute four restructuring plans initiated between 2001 and 2003. Remaining liabilities for severance and facility abandonment are expected to be settled by the end of 2004 or 2005. Management targets additional pre-tax cost savings of $5 million to $20 million in fiscal 2004 from the integration of Life Sciences and Analytical Instruments.
- Capital Expenditures: Expected to range between $20.0 million and $30.0 million for fiscal 2004, dependent on economic conditions.
- Debt Management: The company prepaid $60.0 million of its term loan during the six-month period. It entered into interest rate swaps in January 2004 to convert $100 million of fixed-rate debt to variable rates, reducing the effective interest rate.
- Risks and Contingencies:
- Legal: The company is defending against a class action lawsuit (filed July 2002) and a derivative lawsuit (filed June 2004) alleging misleading statements regarding prospects and revenue recognition. No loss amount can be reasonably estimated.
- Environmental: Accrued $4.4 million for environmental remediation; potential exposure is not expected to be materially different from recorded amounts.
- Market: Results are subject to cyclical downturns in pharmaceutical, semiconductor, and aerospace markets. International sales represent over 50% of total revenue, exposing the company to foreign exchange and geopolitical risks.
Investor Verification Checklist
- Verify the sustainability of the 44% sales growth in the Fluid Sciences segment, which is attributed to a ramp-up in semiconductor and aerospace markets.
- Monitor the progress of the four ongoing restructuring plans and the realization of targeted cost savings ($30M-$45M cumulative vs. 2002 levels).
- Assess the impact of the pending class action and derivative lawsuits on potential future liabilities and management focus.
- Review the company's ability to maintain debt covenants given the leverage ratio and the mix of fixed vs. variable interest rate debt.
- Confirm the timeline for the sale of the Ultraviolet Lighting business and the shutdown of Electroformed Products to ensure no further unexpected charges.